Indication
Advanced Solid Cancers Refractory to PD-1
1 clinical trial
1 product
Clinical trial
Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent TherapyStatus: Completed, Estimated PCD: 2022-03-30
Product
AGEN1884